Categories
Change Password!
Reset Password!
Urine proteomics has a potential to help decipher the pathophysiology and develop novel biomarkers in chronic rheumatic conditions e.g. OA, RA, PsA.
The current diagnostic measures for inflammatory arthritis
lack the required specificity to appropriately divide patients. Thus, new
methods to categorise patients with these conditions needs to be explored.
This study explains whether
urinary proteomic biomarkers specific for various forms of arthritis
(rheumatoid arthritis (RA), psoriatic arthritis (PsA), osteoarthritis (OA)) or
chronic inflammatory conditions (inflammatory bowel disease (IBD)) can be
recognised.
All in all, 50 participants per
group with RA, PsA, OA or IBD and 50 healthy controls were inculcated in the
study. About two-thirds of these populations were randomly assigned as a
training set, while the rest one-third were reserved for validation. Multiple
urinary peptides significantly associated with discrete pathological conditions
were revealed as a result of sequential comparison of one group to the other
four. The classifiers for the five groups were made and tested blind in the validation test set.
These classifers portrayed
superb performance, with an area under the curve between 0.90 and 0.97 per
group. The identified peptide markers revealed novel inflammatory markers along
with dysregulation of collagen synthesis and inflammation.
We cease to know that urinary
peptide signatures can efficiently differentiate between chronic arthropathies
and inflammatory conditions with distinct pathogenesis.
Scientific Reports
Urinary proteomics can define distinct diagnostic inflammatory arthritis subgroups
Stefan Seibert et al.
Comments (0)